Aubrey Rankin has sold RVNC and made no open-market buys since Sep 2020
Pres, Innovation, Tech at Revance Therapeutics, Inc.
SEC CIK 0001818576 · Filings on SEC.gov ↗
$0Bought
$8.7MSold
NoneLast buy
Every filing
9 filings since Sep 2020, newest first
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$247K−2.0%Aug 17
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$1.6M−9.0%Jul 30
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$1.6M−8.0%Jul 28
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$842K−5.0%Mar 5
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$859K−5.0%Feb 3
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$921K−4.0%Jan 4
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$790K−4.0%Dec 2
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$866K−4.0%Oct 30
RVNCSell
Revance Therapeutics, Inc.
Pres, Innovation, Tech
$867K−4.0%Sep 30
Filings come from SEC EDGAR. Not investment advice.